Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Decreases By 60.0%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 14,050 shares, a decline of 60.0% from the April 15th total of 35,087 shares. Based on an average daily trading volume, of 12,279 shares, the short-interest ratio is presently 1.1 days. Approximately 0.9% of the company’s shares are short sold.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Price Performance

NASDAQ AEMD opened at $2.14 on Thursday. The stock’s fifty day moving average price is $2.14 and its 200 day moving average price is $2.84. The company has a market cap of $3.36 million, a price-to-earnings ratio of -0.15 and a beta of 1.50. Aethlon Medical has a 1 year low of $1.36 and a 1 year high of $35.20.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($0.44). Research analysts expect that Aethlon Medical will post -9.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.